News & Resources

Overview

Corporate Profile

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Orexigen developed Contrave® (naltrexone HCI/bupropion HCI) Extended-Release Tablets, which is approved in the United States. Orexigen’s partner for North America, Takeda Pharmaceuticals, markets CONTRAVE in the United States.

Outside of North America, Orexigen's strategy for naltrexone HCI /bupropion HCI is to purMore >>

Stock Quote

OREX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$7.68
Change (%) Stock is Down 0.15 (1.92%)
Volume3,919,818
Apr 01, 2015 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

More >>
DateTitle 
03/30/15Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial OfficerPrinter Friendly Version
03/26/15Orexigen's Mysimba™ Approved in Europe for the Treatment of ObesityPrinter Friendly Version
02/25/15Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2014Printer Friendly Version
02/23/15Orexigen Therapeutics to Speak at the 2015 RBC Capital Markets Global Healthcare ConferencePrinter Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.